Anti-HIV-1 nanotherapeutics: Promises and challenges for the future

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 5301-5314

  Mahajan, Supriya D ^a   Aalinkeel, Ravikumar ^a   Law, Wing Cheung ^b   Reynolds, Jessica L ^a   Nair, Bindukumar B ^a   Sykes, Donald E ^a   Yong, Ken Tye ^d   Roy, Indrajit ^c   Prasad, Paras N ^b   Schwartz, Stanley A ^a  

^a Department of Medicine   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c UNIVERSITY OF DELHI   (India)

^d NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Drug delivery; HAART; HIV; Nano; Nanomedicine; Nanotherapeutics

Indexed keywords

AMPRENAVIR TRANSFERRIN CONJUGATE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INDINAVIR; LOPINAVIR; MICROBICIDE; NANOMATERIAL; NANOPARTICLE; NEVIRAPINE; RILPIVIRINE; RITONAVIR; SAQUINAVIR TRANSFERRIN CONJUGATE; SMALL INTERFERING RNA; STAVUDINE; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TARGETING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOTHERAPY; INFECTION PREVENTION; LIFE CYCLE; NANOTECHNOLOGY; NONHUMAN; REVIEW; RISK ASSESSMENT; SEXUAL TRANSMISSION; SINGLE DRUG DOSE; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; DRUG DESIGN; FORECASTING; HIV INFECTIONS; HIV-1; HUMANS; NANOCAPSULES;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84870352600     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S25871     Document Type: Review

References (109)

1. Bruchez M Jr, Moronne M, Gin P, Weiss S, Alivisatos AP. Semiconductor nanocrystals as fluorescent biological labels. Science. 1998;281(5385):2013-2016.
2. Chan WC, Nie S. Quantum dot bioconjugates for ultrasensitive non-isotopic detection. Science. 1998;281(5385):2016-2018.
3. Pardridge WM. Gene targeting in vivo with pegylated immunoliposomes. Methods Enzymol. 2003;373:507-528.
4. Shi N, Boado RJ, Pardridge WM. Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm Res. 2001a;18(8):1091-1095.
5. Shi N, Zhang Y, Zhu C, Boado RJ, Pardridge WM. Brain-specific expression of an exogenous gene after i.v. administration. Proc Natl Acad Sci U S A. 23, 2001;98(22):12754-12759.
6. Vinogradov S. The second annual symposium on nanomedicine and drug delivery: exploring recent developments and assessing major advances. August 19-20, 2004, Polytechnic University, Brooklyn, NY, USA. Expert Opin Drug Deliv. 2004;1(1):181-184.
7. Yong, KT, Qian J, Roy I, etal. Quantum rod bioconjugates as targeted probes for confocal and two-photon fluorescence imaging of cancer cells. Nano Lett. 2007;7(3):761-765.
8. Lee DE, Koo H, Sun IC, Ryu JH, Kim K, Kwon IC. Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem Soc Rev. 2012;41(7):2656-2672.
9. Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic nanomedicine. Acc Chem Res. 2011;44(10):1029-1038.
10. Kim BY, Rutka JT, Chan WC. Nanomedicine. N Engl J Med. 2010; 363(25):2434-2443.
11. Parboosing R, Maguire GEM, Govender P, Kruger HG. Nanotechnology and the treatment of HIV infection. Viruses. 2012;4:488-520.
12. Armstead AL, Li B. Nanomedicine as an emerging approach against intracellular pathogens. Int J Nanomedicine. 2011;6:3281-3293.
13. Lara HH, Garza-Treviño EN, Ixtepan-Turrent L, Singh DK. Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds. J Nanobiotechnology. 2011;9:30.
14. das Neves J, Amiji M, Sarmento B. Mucoadhesive nanosystems for vaginal microbicide development: friend or foe? Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011;3(4):389-399.
15. Kim JM, Han SH. Immunotherapeutic restoration in HIV-infected individuals. Immunotherapy. 2011;3(2):247-267.
16. Mallipeddi R, Rohan LC. Progress in antiretroviral drug delivery using nanotechnology. Int J Nanomedicine. 2010;5:533-547.
17. Kim PS, Read SW. Nanotechnology and HIV: potential applications for treatment and prevention. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;2(6):693-702.
18. Chawla P, Chawla V, Maheshwari R, Saraf SA, Saraf SK. Fullerenes: from carbon to nanomedicine. Mini Rev Med Chem. 2010;10(8): 662-677.
19. Mamo T, Moseman EA, Kolishetti N, etal. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond). 2010;5(2):269-285.
20. Seale-Goldsmith MM, Leary JF. Nanobiosystems. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1(5):553-567.
21. Hauck TS, Giri S, Gao Y, Chan WC. Nanotechnology diagnostics for infectious diseases prevalent in developing countries. Adv Drug Deliv Rev. 2010;62(4-5):438-448.
22. Wong HL, Chattopadhyay N, Wu XY, Bendayan R. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv Drug Deliv Rev. 2010;62(4-5):503-517.
23. das Neves J, Amiji MM, Bahia MF, Sarmento B. Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv Drug Deliv Rev. 2010;62(4-5):458-477.
24. Gupta U, Jain NK. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv Drug Deliv Rev. 2010;62(4-5):478-490.
25. Boisselier E, Astruc D. Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev. 2009;38(6):1759-1782.
26. Nowacek A, Gendelman HE. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond). 2009;4(5):557-574.
27. Berry CC. Intracellular delivery of nanoparticles via the HIV-1 tat peptide. Nanomedicine (Lond). 2008;3(3):357-365.
28. Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev. 2008;60(8):915-928.
29. Vyas TK, Shah L, Amiji MM. Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin Drug Deliv. 2006;3(5):613-628.
30. Guo P. RNA nanotechnology: engineering, assembly and applications in detection, gene delivery and therapy. J Nanosci Nanotechnol. 2005; 5(12):1964-1982.
31. Pedziwiatr-Werbicka E, Ferenc M, Zaborski M, Gabara B, Klajnert B, Bryszewska M. Characterization of complexes formed by polypropylene imine dendrimers and anti-HIV oligonucleotides. Colloids Surf B Biointerfaces. 2011;83(2):360-366.
32. Lee CC, MacKay JA, Fréchet JMJ, Szoka FC. Designing dendrimers for biological applications. Nat Biotechnol. 2005;23:1517-1526.
33. Chrai SS, Murari R, Ahmad I. Liposomes: A review. Pharmaceut Tech. 2002;26:28-34.
34. Kwon GS, Forrest ML. Amphiphilic block copolymer micelles for nanoscale drug delivery. Drug Develop Res. 2006;67:15-22.
35. Croy S, Kwon G. Polymeric micelles for drug delivery. Curr Pharm Des. 2006;12:4669-4684.
36. Zhang J, Li S, Li X. Polymeric nano-assemblies as emerging delivery carriers for therapeutic applications: A review of recent patents. Recent Pat Nanotechnol. 2009;3:225-231.
37. Bekkara-Aounallah F, Gref R, Othman M, etal. Novel PEGylated nanoassemblies nade of self-assembled squalenoyl nucleoside analogues. Adv Funct Mater. 2008;18:3715-3725.
38. Couvreur P, Stella B, Reddy LH, etal. Squalenoyl nanomedicines as potential therapeutics. Nano Lett. 2006;6:2544-2548.
39. Mason TG, Wilking J, Meleson K, Chang C, Graves S. Nanoemulsions: Formation, structure, and physical properties. J Phys Condens Mat. 2006;18:R635-R666.
40. AZoNano. Nanocapsules and dendrimers-Properties and future applications. Available from: http://www.azonano.com/article.aspx? ArticleID=1649. Accessed December 2, 2011.
41. Torchilin VP. Nanoparticulates as Drug Carriers. London, UK: Imperial College Press; 2006; xxix, 724.516.
42. Bawa R. Nanopharmaceuticals: nanopharmaceuticals. Eur J Nanomed. 2010;3:34-40.
43. Fu A, Gu W, Boussert B, et al. Semiconductor quantum rods as single molecule fluorescent biological labels. Nano Lett. 2006;7:179-182.
44. Liong M, Lu J, Kovochich M, Xia T, etal. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano. 2008;2(5):889-896.
45. Lee JE, Lee N, Kim H, etal. Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery. J Am Chem Soc. 2010;132(2): 552-557.
46. Law WC, Mahajan SD, Kopwitthaya A, etal. Gene silencing of human neuronal cells for drug addiction therapy using anisotropic nanocrystals. Theranostics. 2012;2(7):695-704.
47. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 2001;47:65-81.
48. Elsabahy M, Wooley KL. Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev. 2012;41(7):2545-2561.
49. Liu L, Law WC, Yong KT, etal. Multimodal imaging probes based on Gd-DOTA conjugated quantum dot nanomicelles. Analyst. 2011;136(9): 1881-1886.
50. Ding H, Yong KT, Roy I, etal. Gold nanorods coated with multilayer polyelectrolyte as contrast agents for multimodal imaging. J Phys Chem C. 2007;111:12552.
51. Dorfs D, Krahne R, Falqui A, Manna L, Giannini C, Zanchet D. In: Andrews DL, Scholas GD, Wiederrecht GP, Comprehensive Nanoscience and Technology. Amsterdam, The Netherlands: Academic Press; 2011:219.
52. Cai W, Shin DW, Chen K, etal. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett. 2006;6:669.
53. Hu R, Yong KT, Roy I, etal. Functionalized near-infrared quantum dots for in vivo tumor vasculature imaging. Nanotechnology. 2010;21(14): 145105.
54. Alam MI, Beg S, Samad A, etal. Strategy for effective brain drug delivery. Eur J Pharm Sci. 2010;40(5):385-403.
55. Mallipeddi R, Rohan LC. Nanoparticle-based vaginal drug delivery systems for HIV prevention. Expert Opin Drug Deliv. 2010;7(1): 37-48.
56. Dou H, Grotepas CB, McMillan JM, etal. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol. 2009;183(1):661-669.
57. Nowacek AS, Miller RL, McMillan J, etal. NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond). 2009;4(8):903-917.
58. Dash PK, Gendelman HE, Roy U, etal. Long-acting NanoART elicits potent antiretroviral and neuroprotective responses in HIV-1 infected humanized mice. AIDS. July 20, 2012. [Epub ahead of print.]
59. Shaik N, Pan G, Elmquist WF. Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors. J Pharm Sci. 2008;97(12):5421-5433.
60. Neves JD, Amiji MM, Bahia BF, Sarmento B. Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv Drug Deliv Rev. 2010;62:458-477.
61. Kadiu I, Nowacek A, McMillan J, Gendelman HE. Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine (Lond). 2011;6(6):975-994.
62. Shegokar R, Singh KK. Surface modified nevirapine nanosuspensions for viral reservoir targeting: In vitro and in vivo evaluation. Int J Pharm. 2011;421(2):341-352.
63. Balkundi S, Nowacek AS, Roy U, Martinez-Skinner A, McMillan J, Gendelman HE. Methods development for blood borne macrophage carriage of nanoformulated antiretroviral drugs. J Vis Exp. 2010;(46)pii:2460.
64. Gupta U, Jain NK. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv Drug Deliv Rev. 2010;62(4-5):478-490.
65. Mamo T, Moseman EA, Kolishetti N, Salvador-Morales C, etal. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond). 2010;5(2):269-285.
66. Borgmann K, Rao KS, Labhasetwar V, Ghorpade A. Efficacy of Tat-conjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neurons. AIDS Res Hum Retroviruses. 2011;27(8):853-862.
67. Destache CJ, Belgum T, Goede M, Shibata A, Belshan MA. Antiretroviral release from poly (DL-lactide-co-glycolide) nanoparticles in mice. J Antimicrob Chemother. 2010;65(10):2183-2187.
68. Saiyed ZM, Gandhi NH, Nair MP. Magnetic nanoformulation of azidothymidine 5'-triphosphate for targeted delivery across the bloodbrain barrier. Int J Nanomedicine. 7, 2010;5:157-166.
69. Ramana LN, Sethuraman S, Ranga U, Krishnan UM. Development of a liposomal nanodelivery system for nevirapine. J Biomed Sci. 2010; 17:57.
70. Cheng Y, Li D, Ji B, Shi X, Gao H. Structure-based design of carbon nanotubes as HIV-1 protease inhibitors:atomistic and coarse-grained simulations. J Mol Graph Model. 2010;29(2):171-177.
71. Mahajan SD, Law WC, Aalinkeel R, etal. Nanoparticle-mediated targeted delivery of antiretrovirals to the brain. Methods Enzymol. 2012;509:43-64.
72. Michalet X, Pinaud FF, Bentolila LA, etal. Quantum dots for live cells, in vivo imaging, and diagnostics. Science. 2005;307:538-544.
73. Prasad PN. Introduction in Biophotonics. New York, NY: Wiley; 2003.
74. Prasad PN. Nanophotonics. New York, NY: Wiley; 2004.
75. Mahajan SD, Roy I, Xu G, etal. Enhancing the delivery of anti retroviral drug "Saquinavir" across the blood brain barrier using nanoparticles. Curr HIV Res. 2010;8(5):396-404.
76. Mahajan SD, Reynolds JL, Aalinkeel R, etal. Enhancing the transversing efficiency and efficacy of the anti retroviral drug "saquinavir" using nanotechnology: Implications for nanotherapeutics in neuro-AIDS. HIV Persistance during Therapy. Fourth International Workshop. December 2009. Global Antiviral Journal. 2009;5(2):45-46.
77. Xu L, Liu Y, Chen Z, etal. Surface-engineered gold nanorods: Promising DNA vaccine adjuvant for HIV-1 treatment. Nano Lett. February 28, 2012. [Epub ahead of print.]
78. Kalkanidis M, Pietersz GA, Xiang SD, etal. Methods for nano-particle based vaccine formulation and evaluation of their immunogenicity. Methods. 2006;40(1):20-29.
79. Wang X, Uto T, Akagi T, Akashi M, Baba M. Poly(gamma-glutamic acid) nanoparticles as an efficient antigen delivery and adjuvant system: potential for an AIDS vaccine. J Med Virol. 2008;80(1): 11-19.
80. Tang S, Hewlett I. Nanoparticle-based immunoassays for sensitive and early detection of HIV-1 capsid (p24) antigen. J Infect Dis. 2010; 201(Suppl 1):S59-S64.
81. Lee KB, Kim E-Y, Mirkin CA, Wolinsky SM. The use of nanoarrays for highly sensitive and selective detection of human immunodeficiency virus type 1in plasma. Nano Lett. 2004;4(10):1869-1872.
82. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007;6(6):443-453.
83. Aigner A. Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo. J Biomed Biotechnol. 2006(4): 71659.
84. Higuchi Y, Kawakami S, Hashida M. Strategies for in vivo delivery of siRNAs: recent progress. Bio Drugs. 2010;24(3):195-205.
85. Raviña M, Paolicelli P, Seijo B, Sanchez A. Knocking down gene expression with dendritic vectors. Mini Rev Med Chem. 2010;10(1): 73-86.
86. Buxton DB. Nanomedicine for the management of lung and blood diseases. Nanomedicine (Lond). 2009;4(3):331-339.
87. de Martimprey H, Vauthier C, Malvy C, Couvreur P. Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA. Eur J Pharm Biopharm. 2009;71(3):490-504.
88. de Fougerolles AR. Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther. 2008;19(2):125-132.
89. Toub N, Malvy C, Fattal E, Couvreur P. Innovative nanotechnologies for the delivery of oligonucleotides and siRNA. Biomed Pharmacother. 2006;60(9):607-620.
90. Bonoiu AC, Mahajan SD, Ding H, etal. Nanotechnology approach for drug addiction therapy: gene silencing using delivery of gold nanorod-siRNA nanoplex in dopaminergic neurons. Proc Natl Acad Sci U S A. 2009;106(14):5546-5550.
91. Zhou J, Neff CP, Liu X, etal. Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1infection in humanized mice. Mol Ther. 2011;19(12):2228-2238.
92. Zhou J, Shu Y, Guo P, Smith DD, Rossi JJ. Dual functional RNA nanoparticles containing phi29motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. Methods. 2011;54(2): 284-294.
93. Mahajan SD, Aalinkeel R, Reynolds JL, etal. Nanotherapeutics using an HIV-1 poly A and transactivator of the HIV-1LTR-(TAR-) specific siRNA. Patholog Res Int. 2011;2011:719139.
94. Jiménez JL, Clemente MI, Weber ND, etal. Carbosilane dendrimers to transfect human astrocytes with small interfering RNA targeting human immunodeficiency virus. Bio Drugs. 2010;24(5):331-343.
95. Gonzalo T, Clemente MI, Chonco L, etal. Gene therapy in HIV-infected cells to decrease viral impact by using an alternative delivery method. Chem Med Chem. 2010;5(6):921-929.
96. Bonoiu A, Mahajan SD, Ye L, etal. MMP-9gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res. 2009;1282:142-155.
97. Kim SS, Subramanya S, Peer D, Shimaoka M, Shankar P. Antibody-mediated delivery of siRNAs for anti-HIV therapy. Methods Mol Biol. 2011;721:339-353.
98. Letvin NL. Progress toward an HIV vaccine. Annu Rev Med. 2005; 56:213-223.
99. Mallipeddi R, Rohan LC. Progress in antiretroviral drug delivery using nanotechnology. Int J Nanomedicine. 2010;5:533-547.
100. Kuo YC, Lee CL. Methylmethacrylate-sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood-brain barrier. Colloids Surf B Biointerfaces. 2012;90:75-82.
101. das Neves J, Michiels J, Ariën KK, etal. Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine. Pharm Res. 2012;29(6): 1468-1484.
102. Kuo YC, Chung CY. Solid lipid nanoparticles comprising internal Compritol 888ATO, tripalmitin and cacao butter for encapsulating and releasing stavudine, delavirdine and saquinavir. Colloids Surf B Biointerfaces. 2011;88(2):682-690.
103. Kuo YC, Yu HW. Polyethyleneimine/poly-(γ-glutamic acid)/poly (lactide-co-glycolide) nanoparticles for loading and releasing antiretroviral drug. Colloids Surf B Biointerfaces. 2011;88(1):158-164.
104. Yang L, Chen L, Zeng R, et al. Synthesis, nanosizing and in vitro drug release of a novel anti-HIV polymeric prodrug: chitosan-O-isopropyl-5'-O-d4T monophosphate conjugate. Bioorg Med Chem. 2010;18(1):117-123.
105. Destache CJ, Belgum T, Christensen K, Shibata A, Sharma A, Dash A. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. BMC Infect Dis. 2009;9:198.
106. Baert L, van't Klooster G, Dries W, etal. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm. 2009;72(3):502-508.
107. Wan L, Zhang X, Pooyan S, et al. Optimizing size and copy number for PEG-FMLF (n-formyl-methionyl-leucyl-phenylalanine) nanocarrier uptake by macrophages. Bioconjug Chem. 2008;19(1):28-38.
108. Kaur CD, Nahar M, Jain NK. Lymphatic targeting of zidovudine using surfaceengineered liposomes. J Drug Target. 2008;16(10):798-805.
109. Dou H, Morehead J, Destache CJ, etal. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology. 2007;358(1):148-158.